Gene therapy company Bluebird Bio has revealed this week that the company is spinning off its cancer programs. The biotech announced on Monday its intent to spin off its oncology business in a transition that is expected to take place this year. The company will retain focus on severe genetic disease (SGD) and will launch … Continue reading “Bluebird Bio Is Spinning Off Its Oncology Business”
